Pharmacopoeia Of The People 39-s Republic Of China Pdf Jun 2026
The holds the copyright.
: Continues to align with International Council for Harmonisation (ICH) guidelines (e.g., Q-series guidelines) to improve global drug standard competitiveness. Structure and Content
The Pharmacopoeia of the People's Republic of China (Chinese Pharmacopoeia, ChP) is the supreme official compendium of drug standards in China, covering both traditional Chinese medicine and western medicines. It is recognized by the World Health Organization (WHO) as the official pharmacopoeia of China. Its standards are legally binding, governing the entire lifecycle of a drug in China, from development and production to sales, utilization, supervision, and control.
The Pharmacopoeia is updated every five years to reflect advancements in analytical chemistry, consumer safety, and global harmonization. The 2020 Edition
The 2020 edition of the Chinese Pharmacopoeia is meticulously organized into four volumes, each dedicated to a specific category of pharmaceutical products. Collectively, it includes a total of , marking an increase of 319 new entries, 3,177 revisions, and 10 removals from the previous 2015 edition. The following is a detailed look at each volume: pharmacopoeia of the people 39-s republic of china pdf
The Pharmacopoeia of the People’s Republic of China (ChP), published by the Chinese Pharmacopoeia Commission, is the official compendium of drug standards in China. It serves as a legally binding document ensuring the quality, safety, and efficacy of pharmaceuticals, including chemical drugs, traditional Chinese medicines (TCM), biological products, and excipients. Since its first edition in 1953, the ChP has undergone continuous revision, reflecting China’s rapid pharmaceutical development and increasing alignment with international standards (e.g., ICH, WHO, USP, EP, JP). This essay explores the historical evolution, structural organization, key features, and global significance of the ChP, while also addressing challenges in harmonization.
Dedicated to biological products, such as vaccines and blood products.
Understanding the Chinese Pharmacopoeia is not just about reading standards; it directly translates into laboratory practice. The ChP defines specific requirements for reagents, excipients, and reference standards, which are labeled as "ChP-grade." This designation ensures that the materials used in analytical testing and manufacturing meet the compendial requirements set forth by the Chinese Pharmacopoeia Commission. When a monograph cites a specific analytical method, using ChP-grade reference standards and reagents is essential to achieving valid and reproducible results that will be accepted by Chinese regulators.
The current version, the , was released on July 2, 2020, and implemented on December 30, 2020. It covers a comprehensive range of Traditional Chinese Medicines (TCM), chemical drugs, biological products, and pharmaceutical excipients. Structure of the 2020 Chinese Pharmacopoeia The holds the copyright
Chinese Pharmacopoeia 2020 - English ed. issued ... - Cisema
The 2025 edition builds on this foundation by further aligning Chinese domestic standards with international frameworks, such as the International Council for Harmonisation (ICH) guidelines. It places a heightened focus on: Controlling elemental impurities and residual solvents.
The Pharmacopoeia of the People's Republic of China is a critical publication that has played a vital role in ensuring the quality and safety of medicines in China. The PDF version offers a convenient and accessible way for users to consult the pharmacopoeia, facilitating the evaluation, approval, and use of medicines in China and beyond.
: Includes a total of 6,385 monographs , featuring 159 new additions and 1,101 revisions across its volumes. It is recognized by the World Health Organization
To ensure compliance, professionals should acquire the pharmacopoeia through legitimate streams:
Websites offering free downloads of copyrighted medical standards often bundle files with malicious software.
Focuses on modern pharmaceuticals, including antibiotics, biochemical drugs, and radioactive drugs. Contains 2,712 monographs. Covers vaccines and recombinant DNA products.